CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model

Daniel H. Zimmerman, Patricia Taylor, Alison Bendele, Roy Carambula, Yvonne Duzant, Valeria Lowe, Sean P. O'Neill, Eyal Talor, Kenneth S. Rosenthal

Research output: Contribution to journalArticle

Abstract

The mouse model of collagen induced arthritis (CIA) effectively mimics human disease and thus is useful for testing and development of rheumatoid arthritis (RA) therapies. We developed a Ligand Epitope Antigen Presentation System (LEAPS) peptide hetero-conjugate vaccine containing an epitope of human collagen type II (CEL-2000) that acted as a therapeutic vaccine in the collagen induced arthritis (CIA) mouse model. LEAPS technology converts a small peptide containing a disease specific epitope into an immunogen by attaching it to an immune or T cell binding peptide (I/TCBL). For CEL-2000, a peptide from human collagen type II (254-273) is attached to the I/TCBL peptide from human β2 microglobulin (J). Treatment with CEL-2000 limited disease (CIA) progression, as demonstrated by reduced Arthritic Index (AI) score, and footpad swelling. Efficacy was confirmed by histopathological microscopic examination of tissues at the end of the study. CEL-2000 limited disease progression as well or better than the etanercept (Enbrel) therapeutic control with significantly better histopathological results than the etanercept treated mice. Most interestingly, CEL-2000 therapy modulated serum cytokine levels with an increase in IL-12p70 and IL-10, which are not seen with etanercept therapy, and reduced IL-17 and TNF-α, also seen with etanercept, among other cytokines studied. CEL-2000 was safe and well tolerated for the mice that received 5 injections given every 2 weeks in a 90 day study supporting its potential usage for long term therapy. These studies demonstrate that fewer treatments with CEL-2000 provide therapy at least as effective as etanercept by specifically modulating the disease producing autoimmune response.

Original languageEnglish (US)
Pages (from-to)412-421
Number of pages10
JournalInternational Immunopharmacology
Volume10
Issue number4
DOIs
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

Inbred DBA Mouse
Experimental Arthritis
Collagen Type II
Chemokines
Rheumatoid Arthritis
Vaccines
Cytokines
Serum
Epitopes
Peptides
Therapeutics
Antigen Presentation
Ligands
CEL 2000
Conjugate Vaccines
Interleukin-17
Autoimmunity
Interleukin-10
Arthritis
Disease Progression

Keywords

  • Collagen induced arthritis
  • Regulation of cytokines in autoimmunity
  • Rheumatoid arthritis
  • Therapeutic vaccine
  • Vaccines for autoimmunity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

CEL-2000 : A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. / Zimmerman, Daniel H.; Taylor, Patricia; Bendele, Alison; Carambula, Roy; Duzant, Yvonne; Lowe, Valeria; O'Neill, Sean P.; Talor, Eyal; Rosenthal, Kenneth S.

In: International Immunopharmacology, Vol. 10, No. 4, 01.04.2010, p. 412-421.

Research output: Contribution to journalArticle

Zimmerman, Daniel H. ; Taylor, Patricia ; Bendele, Alison ; Carambula, Roy ; Duzant, Yvonne ; Lowe, Valeria ; O'Neill, Sean P. ; Talor, Eyal ; Rosenthal, Kenneth S. / CEL-2000 : A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. In: International Immunopharmacology. 2010 ; Vol. 10, No. 4. pp. 412-421.
@article{dfa4cab7f36b430283bb44252354539f,
title = "CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model",
abstract = "The mouse model of collagen induced arthritis (CIA) effectively mimics human disease and thus is useful for testing and development of rheumatoid arthritis (RA) therapies. We developed a Ligand Epitope Antigen Presentation System (LEAPS) peptide hetero-conjugate vaccine containing an epitope of human collagen type II (CEL-2000) that acted as a therapeutic vaccine in the collagen induced arthritis (CIA) mouse model. LEAPS technology converts a small peptide containing a disease specific epitope into an immunogen by attaching it to an immune or T cell binding peptide (I/TCBL). For CEL-2000, a peptide from human collagen type II (254-273) is attached to the I/TCBL peptide from human β2 microglobulin (J). Treatment with CEL-2000 limited disease (CIA) progression, as demonstrated by reduced Arthritic Index (AI) score, and footpad swelling. Efficacy was confirmed by histopathological microscopic examination of tissues at the end of the study. CEL-2000 limited disease progression as well or better than the etanercept (Enbrel) therapeutic control with significantly better histopathological results than the etanercept treated mice. Most interestingly, CEL-2000 therapy modulated serum cytokine levels with an increase in IL-12p70 and IL-10, which are not seen with etanercept therapy, and reduced IL-17 and TNF-α, also seen with etanercept, among other cytokines studied. CEL-2000 was safe and well tolerated for the mice that received 5 injections given every 2 weeks in a 90 day study supporting its potential usage for long term therapy. These studies demonstrate that fewer treatments with CEL-2000 provide therapy at least as effective as etanercept by specifically modulating the disease producing autoimmune response.",
keywords = "Collagen induced arthritis, Regulation of cytokines in autoimmunity, Rheumatoid arthritis, Therapeutic vaccine, Vaccines for autoimmunity",
author = "Zimmerman, {Daniel H.} and Patricia Taylor and Alison Bendele and Roy Carambula and Yvonne Duzant and Valeria Lowe and O'Neill, {Sean P.} and Eyal Talor and Rosenthal, {Kenneth S.}",
year = "2010",
month = "4",
day = "1",
doi = "10.1016/j.intimp.2009.12.016",
language = "English (US)",
volume = "10",
pages = "412--421",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - CEL-2000

T2 - A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model

AU - Zimmerman, Daniel H.

AU - Taylor, Patricia

AU - Bendele, Alison

AU - Carambula, Roy

AU - Duzant, Yvonne

AU - Lowe, Valeria

AU - O'Neill, Sean P.

AU - Talor, Eyal

AU - Rosenthal, Kenneth S.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - The mouse model of collagen induced arthritis (CIA) effectively mimics human disease and thus is useful for testing and development of rheumatoid arthritis (RA) therapies. We developed a Ligand Epitope Antigen Presentation System (LEAPS) peptide hetero-conjugate vaccine containing an epitope of human collagen type II (CEL-2000) that acted as a therapeutic vaccine in the collagen induced arthritis (CIA) mouse model. LEAPS technology converts a small peptide containing a disease specific epitope into an immunogen by attaching it to an immune or T cell binding peptide (I/TCBL). For CEL-2000, a peptide from human collagen type II (254-273) is attached to the I/TCBL peptide from human β2 microglobulin (J). Treatment with CEL-2000 limited disease (CIA) progression, as demonstrated by reduced Arthritic Index (AI) score, and footpad swelling. Efficacy was confirmed by histopathological microscopic examination of tissues at the end of the study. CEL-2000 limited disease progression as well or better than the etanercept (Enbrel) therapeutic control with significantly better histopathological results than the etanercept treated mice. Most interestingly, CEL-2000 therapy modulated serum cytokine levels with an increase in IL-12p70 and IL-10, which are not seen with etanercept therapy, and reduced IL-17 and TNF-α, also seen with etanercept, among other cytokines studied. CEL-2000 was safe and well tolerated for the mice that received 5 injections given every 2 weeks in a 90 day study supporting its potential usage for long term therapy. These studies demonstrate that fewer treatments with CEL-2000 provide therapy at least as effective as etanercept by specifically modulating the disease producing autoimmune response.

AB - The mouse model of collagen induced arthritis (CIA) effectively mimics human disease and thus is useful for testing and development of rheumatoid arthritis (RA) therapies. We developed a Ligand Epitope Antigen Presentation System (LEAPS) peptide hetero-conjugate vaccine containing an epitope of human collagen type II (CEL-2000) that acted as a therapeutic vaccine in the collagen induced arthritis (CIA) mouse model. LEAPS technology converts a small peptide containing a disease specific epitope into an immunogen by attaching it to an immune or T cell binding peptide (I/TCBL). For CEL-2000, a peptide from human collagen type II (254-273) is attached to the I/TCBL peptide from human β2 microglobulin (J). Treatment with CEL-2000 limited disease (CIA) progression, as demonstrated by reduced Arthritic Index (AI) score, and footpad swelling. Efficacy was confirmed by histopathological microscopic examination of tissues at the end of the study. CEL-2000 limited disease progression as well or better than the etanercept (Enbrel) therapeutic control with significantly better histopathological results than the etanercept treated mice. Most interestingly, CEL-2000 therapy modulated serum cytokine levels with an increase in IL-12p70 and IL-10, which are not seen with etanercept therapy, and reduced IL-17 and TNF-α, also seen with etanercept, among other cytokines studied. CEL-2000 was safe and well tolerated for the mice that received 5 injections given every 2 weeks in a 90 day study supporting its potential usage for long term therapy. These studies demonstrate that fewer treatments with CEL-2000 provide therapy at least as effective as etanercept by specifically modulating the disease producing autoimmune response.

KW - Collagen induced arthritis

KW - Regulation of cytokines in autoimmunity

KW - Rheumatoid arthritis

KW - Therapeutic vaccine

KW - Vaccines for autoimmunity

UR - http://www.scopus.com/inward/record.url?scp=77949485280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949485280&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2009.12.016

DO - 10.1016/j.intimp.2009.12.016

M3 - Article

C2 - 20074669

AN - SCOPUS:77949485280

VL - 10

SP - 412

EP - 421

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 4

ER -